Pharmacist‐Designed and ‐Implemented Pharmaceutical Care Plan for Antipsychotic‐Induced Movement Disorders

Stoner, Steven C.; Worrel, Jodi A.; Jones, M. B.; Farrar, Cynthia A.; Ramlatchman, Leonard V.

doi:10.1592/phco.20.6.583.35159

Cited by 11 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clozapine seems to have the lowest risk of developing TD among the atypical antipsychotics and has been used to lessen symptoms . Pharmacists are uniquely positioned to administer the Abnormal Involuntary Movement Scale to assess for and monitor the development of TD . Long‐term risks of developing TD when used as adjunctive therapy in MDD are unknown …”

Section: Discussionmentioning

confidence: 99%

Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature

2013

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a chronic mental illness that affects an estimated 5-26% of adults at some time in their lives. Treatment is often started as pharmacotherapy using a single drug such as a selective serotonin reuptake inhibitor. If a patient fails to respond adequately to the initial antidepressant, typically three pharmacotherapy options are available to the practitioner. The dose of the current therapy can be maximized, a change can be made to a different drug, or the current regimen can be augmented with another drug. Atypical antipsychotics have recently become a major focus for augmentation of traditional antidepressant therapy. This review summarizes the evidence for efficacy and safety of augmenting treatment-refractory or treatment-resistant depression with atypical antipsychotics. The National Library of Medicine's MEDLINE database was searched for all English-language articles published from January 1966-December 2011 describing the use of atypical antipsychotics in treatment-resistant depression. The literature retrieved was limited to case series, open-label trials, and randomized controlled trials (RCT). Studies of bipolar depression, psychotic depression, or studies conducted in children and adolescents were excluded. Thirty-five studies using atypical antipsychotics for augmentation treatment of depression were included in this analysis. Trials were identified for aripiprazole (six open-label; three RCT), clozapine (one case series), olanzapine (three open-label, including two case series; four RCT), quetiapine (four open-label; five RCT), risperidone (two open-label; five RCT), and ziprasidone (two open-label). The atypical antipsychotics may be effective as adjunctive therapy in MDD; however, their adverse effect profile may be unfavorable to some patients. Trying at least one alternative treatment strategy after an initial antidepressant is indicated before augmentation is implemented with these agents. If atypical antipsychotics are used, safety and efficacy should be frequently reassessed and dosage should be individualized.

show abstract

Section: Discussionmentioning

confidence: 99%

Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature

2013

View full text Add to dashboard Cite

show abstract

“…Two studies included board certified psychiatric pharmacists (Gable and Stunson, 2010;Tallian et al, 2012). Six provided descriptions of the intervention training provided, and all the intervention training content varied and the personnel delivering the intervention were different (Gisev et al, 2006;Ilickovic et al, 2016;Marques et al, 2013;Salazar-Ospina et al, 2017;Sathienluckana et al, 2018;Stoner et al, 2000). For example, some pharmacists received training by psychiatrists to prepare them to support people living with SPMI (Salazar-Ospina et al, 2017), whereas in the study by Gisev et al, training was delivered by a multidisciplinary team including specialist pharmacists, consumer educators, a psychologist, a mental health nurse and a psychiatrist (Gisev et al, 2006).…”

Section: Pharmacists' Qualifications and Training Provided For Intervention Deliverymentioning

confidence: 99%

Pharmacist-led interventions for people living with severe and persistent mental illness: A systematic review

El-Den

Stewart

et al. 2021

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Objective: People living with severe and persistent mental illness experience poorer physical health, often due to medication and preventable lifestyle factors, and exacerbated by barriers to accessing healthcare services. Pharmacists are well-positioned to improve the physical and mental health of this population. However, little is known about pharmacists’ current practices when providing services to this population nor the impact of pharmacist-led interventions on consumer health outcomes. We undertook a systematic review to identify, describe and assess the effectiveness of pharmacist-led interventions for supporting people living with severe and persistent mental illness and the impact on consumer outcomes. Methods: MEDLINE, Embase, PsycINFO, CINAHL, Web of Science, Scopus, Cochrane Library, International Pharmaceutical Abstracts and ProQuest Dissertations and Theses were searched between January 1990 and April 2020. Full-text studies exploring pharmacist-led interventions in any setting for people living with severe and persistent mental illness were included. A risk of bias assessment was conducted. Results: A total of 37 studies were included. More than half of the pharmacist interventions were multifaceted. The most common components of pharmacist-led interventions included education and/or patient counselling, providing recommendations to healthcare professionals and conducting medication reviews. Multifaceted interventions demonstrated improvements in clinical outcomes, whereas single interventions focused mostly on consumer-reported outcomes. The methodological quality of included studies was moderate-to-high risk of bias and there was considerable heterogeneity in the study design, interventions described, and outcomes reported. Conclusion: There is evidence that pharmacist-led interventions improve consumer-reported and clinical outcomes for people living with severe and persistent mental illness. Pharmacists are capable and have a role in supporting people living with severe and persistent mental illness, either individually or as interprofessional collaborators with other healthcare professionals. Future research should attempt to better understand which particular intervention components have the greatest impact and also evaluate the implementation and long-term sustainability of such interventions.

show abstract

“…308 The pharmacist' s role in the treatment of patients receiving injectable long-acting fluphenazine also has been described. 309 Other authors have described the contributions of pharmacists to the care of patients with psychiatric disorders, especially in hospital settings.…”

Section: Documented Impactmentioning

confidence: 99%

Healthy People 2010: Challenges, Opportunities, and a Call to Action for America's Pharmacists

et al. 2004

View full text Add to dashboard Cite

Pharmacist‐Designed and ‐Implemented Pharmaceutical Care Plan for Antipsychotic‐Induced Movement Disorders

Cited by 11 publications

References 19 publications

Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature

Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature

Pharmacist-led interventions for people living with severe and persistent mental illness: A systematic review

Healthy People 2010: Challenges, Opportunities, and a Call to Action for America's Pharmacists

Contact Info

Product

Resources

About